Literature DB >> 24862365

The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors.

Luisa Ponzoni1, Daniela Braida, Luca Pucci, Donzelli Andrea, Francesca Fasoli, Irene Manfredi, Roger L Papke, Clare Stokes, Giuseppe Cannazza, Francesco Clementi, Cecilia Gotti, Mariaelvina Sala.   

Abstract

RATIONALE: Cigarette smoking is one of the most serious health problems worldwide and people trying to stop smoking have high rates of relapse. Zebrafish (Danio rerio), by combining pharmacological and behavioral assays, is a promising animal model for rapidly screening new compounds to induce smoking cessation.
OBJECTIVES: This study aims to identify possible acetylcholine nicotinic receptors (nAChRs) involved in mediating nicotine (NIC)-induced conditioned place preference (CPP) in zebrafish and investigate the effect of the CC4 and CC26 cytisine derivatives in reducing NIC-induced CPP.
METHODS: CPP was evaluated using a two-compartment chamber, and the zebrafish were given CC4 (0.001-5 mg/kg), CC26 (0.001-1 mg/kg), cytisine (0.1-2.5 mg/kg), and varenicline (1-10 mg/kg) alone or with NIC (0.001 mg/kg). Swimming activity was evaluated using a square observational chamber. The affinity of the nicotinic ligands for native zebrafish brain nAChRs was evaluated by binding studies using [(3)H]-Epibatidine (Epi) and [(125)I]-αBungarotoxin (αBgtx) radioligands, and their subtype specificity was determined by means of electrophysiological assay of oocyte-expressed α4β2 and α7 subtypes.
RESULTS: CC4 and CC26 induced CPP with an inverted U-shaped dose-response curve similar to that of NIC. However, when co-administered with NIC, they blocked its reinforcing or slightly aversive effect. Binding and electrophysiological studies showed that this effect was due to binding to high-affinity heteromeric but not α7-containing receptors.
CONCLUSIONS: We have further characterized CC4 and identified a new compound (CC26) that may be active in inducing smoking cessation. Zebrafish is a very useful model for screening new compounds that can affect the rewarding properties of NIC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24862365     DOI: 10.1007/s00213-014-3619-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  53 in total

1.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

2.  Exacerbation of schizophrenia by varenicline.

Authors:  Robert Freedman
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

Review 3.  Structural and functional diversity of native brain neuronal nicotinic receptors.

Authors:  Cecilia Gotti; Francesco Clementi; Alice Fornari; Annalisa Gaimarri; Stefania Guiducci; Irene Manfredi; Milena Moretti; Patrizia Pedrazzi; Luca Pucci; Michele Zoli
Journal:  Biochem Pharmacol       Date:  2009-05-27       Impact factor: 5.858

Review 4.  Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; John G Spangler; Curt D Furberg
Journal:  CMAJ       Date:  2011-07-04       Impact factor: 8.262

5.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

Review 6.  The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.

Authors:  J Foulds
Journal:  Int J Clin Pract       Date:  2006-05       Impact factor: 2.503

Review 7.  Use of zebrafish as a model to understand mechanisms of addiction and complex neurobehavioral phenotypes.

Authors:  Priya Mathur; Su Guo
Journal:  Neurobiol Dis       Date:  2010-05-20       Impact factor: 5.996

8.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

9.  Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release.

Authors:  Sharon R Grady; Milena Moretti; Michele Zoli; Michael J Marks; Alessio Zanardi; Luca Pucci; Francesco Clementi; Cecilia Gotti
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

10.  John Daly's compound, epibatidine, facilitates identification of nicotinic receptor subtypes.

Authors:  Michael J Marks; Duncan S Laverty; Paul Whiteaker; Outi Salminen; Sharon R Grady; J Michael McIntosh; Allan C Collins
Journal:  J Mol Neurosci       Date:  2009-08-12       Impact factor: 3.444

View more
  7 in total

1.  Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors.

Authors:  Luisa Ponzoni; Daniela Braida; Mariaelvina Sala
Journal:  Psychopharmacology (Berl)       Date:  2016-06-18       Impact factor: 4.530

2.  Conservation of mechanisms regulating emotional-like responses on spontaneous nicotine withdrawal in zebrafish and mammals.

Authors:  Luisa Ponzoni; Gloria Melzi; Laura Marabini; Andrea Martini; Giulia Petrillo; Muy-Teck Teh; Jose V Torres-Perez; Stefano Morara; Cecilia Gotti; Daniela Braida; Caroline H Brennan; Mariaelvina Sala
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-04-24       Impact factor: 5.067

3.  Molecular psychiatry of zebrafish.

Authors:  A M Stewart; J F P Ullmann; W H J Norton; M O Parker; C H Brennan; R Gerlai; A V Kalueff
Journal:  Mol Psychiatry       Date:  2014-10-28       Impact factor: 15.992

4.  Behavioral Effects of Developmental Exposure to JWH-018 in Wild-Type and Disrupted in Schizophrenia 1 (disc1) Mutant Zebrafish.

Authors:  Judit García-González; Bruno de Quadros; William Havelange; Alistair J Brock; Caroline H Brennan
Journal:  Biomolecules       Date:  2021-02-19

Review 5.  Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation.

Authors:  Tasnim S Mohamed; Selwyn S Jayakar; Ayman K Hamouda
Journal:  Front Mol Neurosci       Date:  2015-11-25       Impact factor: 5.639

6.  A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol.

Authors:  Cinzia Citti; Pasquale Linciano; Fabiana Russo; Livio Luongo; Monica Iannotta; Sabatino Maione; Aldo Laganà; Anna Laura Capriotti; Flavio Forni; Maria Angela Vandelli; Giuseppe Gigli; Giuseppe Cannazza
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

7.  Identification of slit3 as a locus affecting nicotine preference in zebrafish and human smoking behaviour.

Authors:  Judit García-González; Alistair J Brock; Matthew O Parker; Riva J Riley; David Joliffe; Ari Sudwarts; Muy-Teck Teh; Elisabeth M Busch-Nentwich; Derek L Stemple; Adrian R Martineau; Jaakko Kaprio; Teemu Palviainen; Valerie Kuan; Robert T Walton; Caroline H Brennan
Journal:  Elife       Date:  2020-03-25       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.